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Background: To evaluate the prognostic value of preoperative tumor markers, cancer antigen 15-3 (CA 15-3) and
carcinoembryonic antigen (CEA), in breast cancers.
Patients and methods: Preoperative CA 15-3 and CEA levels of 1681 patients were measured. The association of
both tumor markers levels with clinicopathological parameters and outcomes was investigated by univariate and
multivariate analyses.
Results: Among 1681 patients, elevated preoperative CA15-3 and CEA levels were identiﬁed in 176 and 131 patients,
respectively. Higher preoperative CA 15-3 and CEA levels were signiﬁcantly associated with a larger tumor size, axillary
node metastases, and advanced stage. Patients with elevated CA 15-3 and CEA levels showed worse survival, even in
stage-matched analysis. Patients with normal levels of both CA15-3 and CEA showed better survival than those with
one or both markers levels elevated. In multivariate analysis, elevated preoperative CA 15-3 and CEA levels were
independent prognostic factors. The statistical signiﬁcance of elevated preoperative tumor markers levels on survival
was solidiﬁed with longer follow-up and larger study population.
Conclusions: Elevated preoperative CA 15-3 and CEA levels are associated with tumor burden and showed
independent prognostic signiﬁcance. Therefore, new treatment strategies are necessary for patients with elevated
preoperative CA 15-3 and CEA levels in clinical practice.
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introduction
Breast cancer is the most frequently occurring cancer in
women from western countries and continues to be the most
common fatal cancer together with lung, bronchus and
colorectum cancers [1]. It is also the second most common
malignancy in Korean women [2]. Despite the rising incidence
of breast cancer, the survival rates have improved in recent
years due to earlier detection and an increasing use of more
effective systemic treatments based on prognostic factors [3].
Therefore, identifying prognostic and predictive factors is
important to assist in decision making about treatment and to
improve survival.
Along with the traditional prognostic factors such as tumor
size, tumor grade, and lymph node status [4], the prognostic
value of serum tumor markers has been investigated in breast
cancer [5–8]. Some studies suggested that elevated
carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA
15-3) levels provided the signiﬁcant prognostic information;
however, others reported no independent value of serum
tumor markers [5–7]. Recently, Maric et al. [8] reviewed the
role of serum tumor markers in breast cancer and they pointed
out conﬂicting results of its prognostic value and rather
emphasized the necessity of more extensive investigations for
improved and a more cost-effective management of breast
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cancer. The American Society of Clinical Oncology (ASCO)
guidelines do not currently recommend the use of serum CA
15-3 and CEA for breast cancer screening, as a routine
surveillance tool or for therapeutic response monitoring due to
inconsistent ﬁndings of their sensitivity and speciﬁcity [9].
However, serum tumor markers such as CA 15-3 and CEA are
the most widely used serum tumor markers for surveillance
purposes and treatment response in clinical practice [10–13].
Previously, we reported that patients with elevated
preoperative levels of CA 15-3 and CEA had worse outcomes
than those with normal levels by stage-matched and
multivariate analyses [14]. However, our previous study had a
relatively short follow-up duration and a small sample size.
Therefore, we aimed to reconﬁrm the prognostic value of
preoperative CA 15-3 and CEA levels while overcoming the
previous limitations. We reinvestigated the data of our previous
study cohort of 740 patients with extended follow-up and then




From April 1999 to December 2006, we investigated serum CA 15-3 and
CEA concentration levels from a total of 1681 patients who were treated for
stage I–III invasive breast cancer at Yonsei University Severance Hospital;
740 patients (group I) who had breast surgery between April 1999 and
December 2003 [14] and another 941 patients (group II) who had breast
surgery between January 2004 and December 2006. We excluded patients
with stage IV disease at diagnosis, carcinoma in situ, unknown TNM
stage and receiving neoadjuvant chemotherapy. All data including serum
CA 15-3 and CEA levels at the time of diagnosis were obtained from the
Severance Hospital Breast Cancer Registry, which is a prospectively
maintained database that includes clinical and pathological information,
treatment modality, and details of outcomes including disease recurrence
and death. Retrospectively to conﬁrm the signiﬁcance of preoperative
serum CA 15-3 and CEA levels in this longer follow-up study, we ﬁrst
reinvestigated the survival outcomes of group I and then evaluated the
relationship between the level of tumor markers, clinicopathological
characteristics and survival outcomes in a larger study population
including groups I and II.
Management of all patients was based on international guidelines and
adjuvant treatment with radiotherapy, chemotherapy and hormone therapy
was not altered according to the marker levels. TNM staging was based on
the sixth American Joint Committee on Cancer criteria. To detect local or
distant relapse, clinical follow-up was carried out every 6 to 12 months,
which included recording patient’s history, physical examination,
laboratory tests of CEA, CA 15-3, complete blood counts, and liver
function test, chest radiography, mammography, breast and
abdominopelvic ultrasonography, and bone scans. In addition, a computed
tomography (CT) scan or a ﬂuorine-18 ﬂuorodeoxyglucose positron
emission tomography (FDG PET)/CT scan was carried out if necessary.
tumor marker analysis
We measured the concentration of serum tumor markers by using
automated immunoanalyzer systems using a chemiluminescent








n % n % n %
Age (years)
≤35 75 10.1 54 5.7 0.001 129 7.7
>35 665 89.9 887 94.3 1552 92.3
Tumor size
T1 410 55.4 589 62.6 <0.001 999 59.4
T2 308 41.6 343 36.5 651 38.7
≥T3 22 3.0 9 1.0 31 1.8
Nodal status
N0 429 58.0 633 67.3 <0.001 1062 63.2
N1 183 24.7 221 23.5 404 24.0
N2 86 11.6 56 6.0 142 8.4
N3 42 5.7 31 3.3 73 4.3
TNM stage
I 283 38.2 452 48.0 <0.001 735 43.7
II 329 44.5 400 42.5 729 43.4
III 128 17.3 89 9.5 217 12.9
HG (n = 1420)
I 123 19.6 187 23.6 0.018 310 21.8
II 316 50.3 416 52.5 732 51.5
III 189 30.1 189 23.9 378 26.6
ER (n = 1648)
Negative 267 37.6 295 31.4 0.009 562 34.1
Positive 443 62.4 643 68.6 1086 65.9
PR (n = 1649)
Negative 387 54.4 349 37.2 <0.001 736 44.6
Positive 324 45.6 589 62.8 913 55.4
HER2 (n = 1637)
Negative 434 62.1 801 85.4 <0.001 1235 75.4
Positive 265 37.9 137 14.6 402 24.6
CA 15-3
Normal (≤20.11) 648 87.6 857 91.1 0.020 1505 89.5
Elevated (>20.11) 92 12.4 84 8.9 176 10.5
CEA
Normal (≤3.88) 661 89.3 889 94.5 <0.001 1550 92.2
Elevated (>3.88) 79 10.7 52 5.5 131 7.8
Surgery
BCS 218 29.5 352 37.4 0.001 570 33.9
TM 522 70.5 589 62.6 1111 66.1
Chemotherapy
None 149 20.1 259 27.5 <0.001 408 24.3
Done 591 79.9 682 72.5 1273 75.7
Endocrine therapy
None 247 33.4 270 28.7 0.037 517 30.8
Done 492 66.6 671 71.3 1163 69.2
Radiation therapy
None 403 54.5 516 54.8 0.878 919 54.7
Done 337 45.5 425 45.2 762 45.3
TNM, tumor-node-metastasis; HG, histologic grade; ER, estrogen receptor;
PR, progesterone receptor; HER2, human epidermal growth factor receptor
2; CA 15-3, cancer antigen 15-3; CEA, carcinoembryonic angigen; BCS,
breast conserving surgery; TM, total mastectomy.
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immunoassay for CEA (ADVIA Centaur, Bayer HealthCare LLC
Diagnostic Division, NY) and CA 15-3 (VITROS ECi Immunodiagnostic
System, Ortho-Clinical Diagnostics, Inc., NY). We deﬁned the cut-off
values of tumor marker as the 95th percentile of healthy individuals,
which was already used in our previous study (CA 15-3: 20.11 U/L, CEA:
3.88 ng/ml) [14]. Tumors with ≥10% nuclear-stained cells were considered
positive for the estrogen receptor (ER) and progesterone receptor (PR).
Human epidermal growth factor receptor 2 (HER2) immunohistochemistry
(IHC) was carried out using the HercepTest™ (DAKO, Glostrup,
Denmark) and interpreted as 0, 1+, 2+, or 3+. HER2 was considered
positive in cases with an IHC 3+ score.
statistical analysis
The difference between proportions was evaluated by the chi-square test.
Disease-free survival (DFS) was deﬁned to be from the time of surgery to the
locoregional recurrence, distant metastasis, and death before recurrence.
Distant relapse-free survival (DRFS) was deﬁned as the time from surgery to
the distant recurrence. Overall survival (OS) was deﬁned to be from the time
of surgery to death from any cause. DFS and OS were estimated using the
Kaplan–Meier method and the group differences in survival time were tested
using the log-rank test. Multivariate Cox’s proportional hazard analysis was
carried out to compare and identify independent prognostic factors for DFS,
DRFS and OS and to calculate hazard ratios. All signiﬁcant parameters in the
univariate analysis were entered into a multivariate model. All reported P
values are two-sided, and P values <0.05 were considered signiﬁcant. SPSS for
Windows (version 15.0) was used for all statistical analyses.
results
The median age of the study population was 48 years (range
20–88 years) and the median follow-up time was 72 months
(range 0.8–143.6 months). The median follow-up duration was
extended to 98.8 months for the previously reported group I
patients and was 63.0 months for the newly added 941 patients
(group II). The general characteristics of the study population
are summarized in Table 1. Compared with the group I
patients, the group II patients were older, detected earlier, had
favorable characteristics, and a few number of elevated
preoperative tumor marker levels. During follow-up, among
the total study population, recurrence occurred in 208 patients
(ﬁrst relapse: local recurrence alone n = 32, systemic recurrence
alone n = 124, both local and systemic recurrences n = 52) and
death occurred in 150 patients.
Survival curves of group I with an extended follow-up
duration are shown in Figure 1. Elevated CA 15-3 or CEA
levels were clearly associated with poor DFS and OS,
respectively (Figure 1A, B, D, and E). Patients with normal
levels of both CA 15-3 and CEA showed better DFS and OS
than those with elevated either one or both markers levels
(P < 0.001). Elevation of either one marker level was associated
with signiﬁcantly better DFS (P = 0.022) and an improved
trend of OS (P = 0.08) than elevation of both markers
(Figure 1C and F). Using the longer follow-up in this study,
the statistical signiﬁcance was reafﬁrmed from the previous
study [14].
Elevated CA 15-3 and CEA levels were identiﬁed in 176
(10.5%) and 131(7.8%) patients, respectively, among whole
group I and II patients (Table 1). The correlation between
serum CA 15-3 and CEA levels and clinicopathological
characteristics are shown in Table 2. Similar to the previous
study [14], both CA 15-3 and CEA levels were correlated with
Figure 1. Survival curves of group I with an extended follow-up duration. Disease-free survival (DFS) according to preoperative cancer antigen 15-3 (CA
15-3) (A), carcinoembryonic antigen (CEA) (B), and combination of both markers levels (C) and overall survival (OS) according to preoperative CA 15-3
(D), CEA (E) and combination of both the markers (F). The bold line represents patients with normal levels and dotted line represents patients with
elevated levels (A, B, D and E). The bold line represents patients with normal levels of both the markers, the dotted line represents patients with elevated
either marker, and the chain line represents patients with elevated both markers (C and F).
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larger tumor size and advanced nodal stage, but not with ER
nor PR expressions. Higher concentration of CA 15-3 was
related to histologic grade III tumors and higher concentration
of CEA was correlated with HER2 positivity in the current
study. Since adjuvant treatment was not determined by tumor
marker levels, there was no difference in adjuvant treatment
according to CA 15-3 and CEA levels, but more patients with
elevated CA15-3 levels received chemotherapy and this was not
statistically signiﬁcant (supplementary Table S1, available at
Annals of Oncology online).
In our study population of 1681 patients, elevated CA 15-3
and CEA levels were signiﬁcantly associated with worse DFS
and OS (Figure 2). In this longer follow-up and larger study
population, the statistical signiﬁcance was more intensiﬁed and
the survival curves were distinctively different according to
tumor markers. In tumor stage-matched analysis, patients with
elevated CA 15-3 levels showed signiﬁcantly worse DFS and OS
in stages I (P = 0.042 and 0.002, respectively) and II (P < 0.001
and P = 0.034, respectively), but not in stage III (supplementary
Figure S1, available at Annals of Oncology online). By analysis of
CEA levels, an elevated CEA group showed a signiﬁcantly worse
DFS and OS in all stages I–III (supplementary Figure S2,
available at Annals of Oncology online).
Multivariate analysis adjusting for the most important
conventional prognostic factors revealed that elevated
preoperative CA 15-3 and CEA levels were independent
prognostic factors in DFS, DRFS and OS. Traditional
clinicopathological factors such as age, tumor size, node
metastasis, and ER status also had independent prognostic
power in the Cox’s models (Table 3). Both CA 15-3 and CEA
levels were elevated in 28 patients, either CA 15-3 or CEA was
elevated in 251 patients, and the remaining 1402 patients had
normal ranges of both the markers. Patients with normal levels
of both the markers showed the best DFS and OS.
Subsequently, those with either one elevated marker level
demonstrated better survival, and ﬁnally, those with both
elevated markers presented the worst survival (both normal
versus either elevated, P < 0.001 for DFS, and P < 0.001 for OS;
and both normal versus both elevated, P < 0.001 for DFS, and
P < 0.001 for OS) (Figure 3).
discussion
The prognostic value of preoperative serum tumor marker CA
15-3 and CEA was demonstrated in our previous study, which
included 740 patients with a median follow-up of 37.2 months
[14]. Our previous ﬁndings were reconﬁrmed and even
solidiﬁed in the present study with an extended follow-up of
98.8 months (Figure 1). Nine hundred and forty-one patients
were added to the previous study population of 740, and the
current analysis was carried out in a larger study population of
1681 with a median follow-up of 72 months.
With the activation of a national screening program, the
proportion of screening-detection remarkably increased from
5.0% to 32.6% and the incidence of stage I breast cancer also
increased from 19.6% to 34.8% between 1996 and 2008 in
Korea [15]. As expected, the incidence of patients with elevated
preoperative levels of serum CA 15-3 and CEA decreased along
with the increase in early breast cancer patients in the current
study (Table 1). This ﬁnding supports the proposed association
of tumor burden and elevated levels of serum tumor markers.
The preoperative serum CEA and CA 15-3 levels are associated
with the tumor size and lymph node metastasis which
represents tumor burden [14, 16, 17] and signiﬁcantly higher
levels of CEA and CA 15-3 were seen in patients with
advanced disease than in those with locoregional breast cancer
[9, 13, 18]. The current study also demonstrated the
association of higher levels of CA 15-3 and CEA with tumor
burden such as larger tumor size, node metastases, and
advanced stage in a large study population with longer follow-
up. Although the association of tumor markers and tumor
biological factors is not well established [19], the serum CA 15-
3 level was related to the poor histological grade in agreement
with the recent study by Molina et al. [5, 20]. The relationship
between higher levels of CEA and HER2 expression needs to
be further investigated.
Since elevated levels of CA 15-3 and CEA are related to the
tumor burden and higher levels may indicate vascularization of
the tumor with an increased likelihood of occult systemic
Table 2. Correlation between serum CA 15-3 and CEA level and
clinicopathological factors in a total of 1681 patients
CA 15-3 CEA
Mean SD P Mean SD P
Age (years)
≤35 12.6275 5.92382 0.290 1.5843 2.55522 0.148
>35 12.0246 6.24367 2.0067 3.23030
Tumor size
T1 11.1831 4.99665 <0.001 1.5955 1.35554 <0.001
T2 12.3598 6.76206 2.2388 4.28705
≥T3 14.1071 7.40522 2.3687 3.13484
Nodal status
N0 11.5717 6.03416 <0.001 1.8288 2.54956 0.054
N1 12.2733 5.75976 2.1459 4.44273
N2 13.9239 7.14502 2.2219 3.22985
N3 14.6074 7.95814 2.6600 2.98600
TNM stage
I 11.1831 4.99665 <0.001 1.5955 1.35554 <0.001
II 12.3598 6.76206 2.2388 4.28705
III 14.1071 7.40522 2.3687 3.13484
HG
I 11.2683 5.38122 0.023 1.8213 3.60024 0.629
II 12.2128 6.08949 1.9909 3.22634
III 12.5184 6.99338 2.0506 2.86661
ER
Negative 12.3451 7.19094 0.194 2.0110 3.57443 0.534
Positive 11.9224 5.71791 1.9110 2.81601
PR
Negative 12.3183 6.72778 0.137 2.0408 3.28881 0.259
Positive 11.8575 5.85121 1.8677 2.92695
HER2
Negative 11.9643 6.31912 0.250 1.8405 3.28933 0.014
Positive 12.3789 6.11875 2.2762 2.42616
CA 15-3, cancer antigen 15-3; CEA, carcinoembryonic angigen; SD,
standard deviation; TNM, tumor-node-metastasis; HG, histologic grade;
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal
growth factor receptor 2.
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metastases [21, 22], elevated CA 15-3 and CEA concentration
at initial presentation could be predictive of poor breast cancer
outcome [23]. In agreement with other studies demonstrating
signiﬁcant association between the preoperative tumor marker
levels and the survival outcome [14, 21, 24, 25], the elevated
preoperative CA 15-3 or CEA levels were signiﬁcantly
Figure 2. Disease-free survival (DFS) according to preoperative CA 15-3 (A) and CEA levels (B) and overall survival (OS) according to preoperative CA 15-
3 (C) and CEA levels (D) in group I and II patients. The bold line represents patients with normal levels and the dotted line represents patients with
elevated levels.
Table 3. Cox’s regression analysis according to age, stage, estrogen receptor status, and serum markers in a total of 1681 patients
DFS DRFS OS
HR CI P HR CI P HR CI P
Age (years)
>35
≤35 0.594 0.396–0.890 0.012 0.557 0.365–0.850 0.007 0.531 0.329–0.856 0.009
Tumor size
≤2 cm
>2 cm 1.431 1.094–1.871 0.009 1.499 1.125–1.998 0.006 1.540 1.090–2.174 0.014
Node
Negative
Positive 2.481 1.888–3.260 <0.001 2.632 1.962–3.531 <0.001 2.374 1.678–3.357 <0.001
ER
Negative
Positive 0.727 0.557–0.948 0.019 0.722 0.544–0.959 0.024 0.516 0.370–0.720 <0.001
CA15-3
Normal
Elevated 1.863 1.340–2.589 <0.001 1.972 1.398–2.781 <0.001 2.020 1.359–3.003 0.001
CEA
Normal
Elevated 2.134 1.493–3.051 <0.001 2.062 1.411–3.014 <0.001 2.601 1.709–3.958 <0.001
DFS, disease-free survival; DRFS, distant recurrence-free survival; OS, overall survival; HR, hazard ratio; CI, conﬁdence interval; ER, estrogen receptor; CA
15-3, cancer antigen 15-3; CEA, carcinoembryonic angigen.
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associated with poor DFS (P < 0.001 and P < 0.001,
respectively) and OS (P < 0.001 and P < 0.001, respectively)
(Figure 2), even in a stage-matched analysis (supplementary
Figures S1 and S2, available at Annals of Oncology online).
With a longer follow-up and a larger population of the present
study, the prognostic signiﬁcance of tumor marker elevation
became more conﬁdent and extended to almost all stages. The
prognostic signiﬁcance was also maintained in the multivariate
analysis with the addition of other traditional prognostic
factors such as age, tumor size, lymph node metastasis, and ER
status (Table 3).
Although the ASCO panel does not recommend therapeutic
decisions be based on the serum tumor marker status [9],
several studies showed that the preoperative concentration of
tumor markers could be useful in combination with other
factors in deciding whether adjuvant chemotherapy should be
administered [5, 13, 23, 26]. Furthermore, higher levels may
reﬂect an increased likelihood of occult systemic metastases
[21] and the study evaluating early treatment based on
increasing tumor marker concentrations showed improved
outcomes compared with controls [27]. Compared with the
results of previous study [14], the prognostic value of the
combination of both marker levels was further intensiﬁed with
a longer follow-up and with a larger study population. Patients
with either one or both markers elevated showed signiﬁcantly
worse survival outcomes than those with both normal ranges
of markers in the current study. Therefore, elevated
preoperative serum tumor markers could be useful in
discriminating high-risk groups and in deciding adjuvant
systemic treatment, for which the hypothesis should be
veriﬁed.
In conclusion, our previous ﬁndings of independent
prognostic signiﬁcance of elevated preoperative serum CA 15-3
and CEA levels [14] are reconﬁrmed with the extended follow-
up and larger study population in the present analyses.
Preoperative serum CA 15-3 and CEA levels can provide
additional prognostic information and may be useful in
treatment implementation. Therefore, both the markers could
be considered for the risk evaluation and determination of
adjuvant treatment strategies in clinical practice, although this
hypothesis should be further validated. Further clinical trials
based on the tumor marker levels are necessary.
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Background: Circulating tumor cells (CTCs) can provide the basis for a liquid biopsy and may guide the use of
targeted therapies. We report on unbiased quantiﬁcation of Her-2 protein expression of CTCs.
Patients and methods: Her-2 assessment of CTCs was carried out using the CellSearch® system in 103 metastatic
(M1) and 88 non-metastatic (M0) breast-cancer patients. Expression of Her-2 on CTCs was determined by a manual
review and an automated algorithm using Her-2- ﬂuorescein isothiocyanate (FITC) ﬂuorescence of leukocytes to
determine the Her-2-expression threshold in each sample.
Results: Her-2 expression of CTCs varied greatly within and among patients compared with Her-2 expression of
leukocytes. In M1 patients, a threshold of 75% of Her-2 positive CTCs in patients with ≥5 CTCs was set. Applying this
threshold, 9% of M1 patients with Her-2-negative primary tumors had Her-2-positive CTC status and 29% of M1
patients with Her-2-positive primary tumors had Her-2-negative CTC status. No Her-2 discrepancy was observed
between CTCs and primary tumors in M0 patients.
Conclusions: Our ﬁndings demonstrate that Her-2 expression is heterogeneous among CTCs within each patient. We
show the feasibility of unbiased quantitative and reproducible assessment of treatment targets on CTCs, opening a
path towards personalized treatment.
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